SEC Form 4 · accession 0001209191-19-016902
Forte Biosciences, Inc. · FBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark G Foletta
Officer — EVP & Chief Financial Officer
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 6:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419041
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $11.00 | Mar 1, 2019 | A | 75,000 | A | — | Feb 28, 2029 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F125% of the shares vest on 3/1/2020 amd the balance of the shares vest monthly thereafter.